These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Torsade de pointes induced by N-acetylprocainamide. Chow MJ; Piergies AA; Bowsher DJ; Murphy JJ; Kushner W; Ruo TI; Asada A; Talano JV; Atkinson AJ J Am Coll Cardiol; 1984 Sep; 4(3):621-4. PubMed ID: 6206104 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans. Funck-Brentano C; Light RT; Lineberry MD; Wright GM; Roden DM; Woosley RL J Cardiovasc Pharmacol; 1989 Sep; 14(3):364-73. PubMed ID: 2476614 [TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide. Winkle RA; Jaillon P; Kates RE; Peters F Am J Cardiol; 1981 Jan; 47(1):123-30. PubMed ID: 6161534 [TBL] [Abstract][Full Text] [Related]
5. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. Roden DM; Reele SB; Higgins SB; Wilkinson GR; Smith RF; Oates JA; Woosley RL Am J Cardiol; 1980 Sep; 46(3):463-8. PubMed ID: 6158263 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of N-acetylprocainamide in long-term treatment of ventricular arrhythmias. Atkinson AJ; Lertora JJ; Kushner W; Chao GC; Nevin MJ Clin Pharmacol Ther; 1983 May; 33(5):565-76. PubMed ID: 6188570 [TBL] [Abstract][Full Text] [Related]
7. Electrophysiologic properties and antiarrhythmic mechanisms of intravenous N-acetylprocainamide in patients with ventricular dysrhythmias. Sung RJ; Juma Z; Saksena S Am Heart J; 1983 May; 105(5):811-9. PubMed ID: 6189384 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects. Wierzchowiecki M; Michałowska D; Lowicki Z; Ochotny R; Grześkowiak A; Tomaszkiewicz T Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):272-6. PubMed ID: 6161089 [TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics and pharmacodynamics of procainamide in horses after intravenous administration. Ellis EJ; Ravis WR; Malloy M; Duran SH; Smyth BG J Vet Pharmacol Ther; 1994 Aug; 17(4):265-70. PubMed ID: 7525982 [TBL] [Abstract][Full Text] [Related]
16. Circadian changes in procainamide and N-acetylprocainamide kinetics in the rat. Bruguerolle B; Jadot G J Pharm Pharmacol; 1985 Sep; 37(9):654-6. PubMed ID: 2416904 [TBL] [Abstract][Full Text] [Related]
17. Use of procainamide in chronic ambulatory peritoneal dialysis: report of a case. Kroboth PD; Mitchum K; Puschett JB Am J Kidney Dis; 1984 Jul; 4(1):78-9. PubMed ID: 6204527 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of N-acetylprocainamide in patients profiled with a stable isotope method. Atkinson AJ; Ruo TI; Piergies AA; Breiter HC; Connelly TJ; Sedek GS; Juan D; Hubler GL; Hsieh AM Clin Pharmacol Ther; 1989 Aug; 46(2):182-9. PubMed ID: 2474402 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the pharmacokinetic and pharmacodynamic properties of procainamide and N-acetylprocainamide. Atkinson AJ; Ruo TI; Piergies AA Angiology; 1988 Jul; 39(7 Pt 2):655-67. PubMed ID: 2457345 [TBL] [Abstract][Full Text] [Related]
20. Dose-ranging trial of N-acetylprocainamide in patients with premature ventricular contractions. Atkinson AJ; Lee WK; Quinn ML; Kushner W; Nevin MJ; Strong JM Clin Pharmacol Ther; 1977 May; 21(5):575-87. PubMed ID: 322922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]